CTLA4 and renal cell carcinoma: As a promising strategy, ICI therapies that block PD-1 or T-lymphocyte-associated antigen 4 (CTLA-4) signaling are being rapidly developed for cancer treatment and showed superior efficacy for intermediate- and poor-risk RCC [186].